An experimental drug can reduce the toxic changes in tau proteins known to damage neurons in brains with Alzheimer's disease, researchers from Yale School of Medicine and Johns Hopkins University report.
Nov 6, 2023
0
83
Existing and emerging cancer drugs could be repurposed as therapies to be tested in clinical trials for people at genetic risk of Alzheimer's disease, according to a new study published in Science Advances. Research combining ...
Nov 10, 2021
0
75
InSysBio continues to investigate the mechanisms underlying Alzheimer's disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The QSP model describing the tau protein was published in PLOS ONE.
Feb 28, 2018
0
64
One of the earliest signs of Alzheimer's disease is a decline in glucose levels in the brain. It appears in the early stages of mild cognitive impairment—before symptoms of memory problems begin to surface. Whether it is ...
Jan 31, 2017
0
28
Autopsies have revealed that some individuals develop the cellular changes indicative of Alzheimer's disease without ever showing clinical symptoms in their lifetime.
May 2, 2014
0
0
With advancing age, highly-evolved brain circuits become susceptible to molecular changes that can lead to neurofibrillary tangles—a hallmark of Alzheimer's Disease, Yale researchers report the week of March 17 in the Proceedings ...
Mar 18, 2014
1
0
